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Abstract
Background: Increasing evidence suggests that cell therapy improves functional recovery in experimental models
of stroke and myocardial infarction. So far only small pilot trials tested the effects of cell therapy in stroke patients,
whereas large clinical trials were conducted in patients with ischemic heart disease. To investigate the therapeutic
benefit of cell therapy to improve the recovery after stroke, we determined the efficacy of bone marrow derived
mononuclear cells, which were shown to improve the recovery in experimental and clinical acute myocardial
infarction studies, in a rat stroke model.
Methods: Adult male Wistar rats were randomly assigned to receive either five million human bone marrow
mononuclear cells (hBMC) or placebo intraarterially 3 days after photothrombotic ischemia. For immunosuppression
the animals received daily injections of cyclosporine throughout the experiment, commencing 24 hours before the
cell transplantation. A battery of behavioral tests was performed before and up to 4 weeks after ischemia.
Results: Body temperature and body weight revealed no difference between groups. Neurological deficits
measured by the Rotarod test, the adhesive-removal test and the cylinder test were not improved by hBMC
transplantation compared to placebo.
Conclusions: This study demonstrates that hBMC do not improve functional recovery when transplanted
intraaterially 3 days after the onset of focal cerebral ischemia. A possible reason for the failed neurological
improvement after cell therapy might be the delayed treatment initiation compared to other experimental stroke
studies that showed efficacy of bone marrow mononuclear cells.
Background
Stroke is the second leading cause of death after myo-
cardial infarction and the most frequent cause of adult
disability [1,2]. For both cardiovascular and cerebrovas-
cular disease cell therapy emerged as a promising thera-
peutic option [3-5]. In animal models of focal cerebral
ischemia and myocardial infarction cells of various
sources were shown to improve outcome [6-11]. In con-
trast to clinical studies on ischemic heart disease, in
which cell therapies were thoroughly investigated, only
small pilot trials of cell treatment in stroke patients
were performed [12,13]. Several reasons may explain the
difficulties in translation from animal stroke models to
the human situation including open questions regarding
t h es o u r c eo fc e l l s ,t h eo p t i m a ld o s eo fc e l l s ,t h er o u t e
of delivery and the time of treatment after the onset of
ischemia. Considerable ethical constraints exist regard-
ing the use of embryonic and fetal stem cells [14]. The
preparation of autologous mesenchymal stem cells
requires cell cultivation which might delay treatment
initiation beyond a therapeutic time window within that
therapy is effective [15,16]. Intravenous administration
of cells is the least invasive method of delivery but
transplanted cells only partly migrate to the infarcted
brain [17]. A direct, intracerebral transplantation can
reliable target a large number of cells closely to the
infarct [18]. However, feasibility and safety issues
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meet the translational roadblocks we aimed to investi-
gate the efficacy of a cell therapy in a rat stroke model
that was shown to be logistically feasible and efficient in
a clinical study of patients with myocardial infarction.
The REPAIR-AMI trial is a large double-blind, rando-
mized, multicenter study in which progenitor cells
derived from bone marrow were intracoronary infused
into the infarct artery 3 to 7 days after myocardial
infarction [19]. The bone marrow mononuclear cells
used in this study can be easily obtained by bone mar-
row aspiration without extensive preparation or cultiva-
tion before transplantation. As performed in the
REPAIR-AMI trial we used an intraarterial injection for
cell transplantation. This approach is routinely per-
formed by neurointerventionalists for drug delivery and
was shown to be feasibly and safe in acute stroke
patients.
Methods
Photothrombotic ischemia model
All animal procedures were carried out in accordance
with national and international regulations and approved
by the local ethics committee. Experiments were per-
formed on adult male Wistar rats (Charles River, Sulz-
feld, Germany; 280 to 320 g body weight), which had
free access to food and water. Animals were anesthe-
tized with an intraperitoneal injection of ketamine
hydrochloride (100 mg/kg body weight; Ketanest) and
xylazine hydrochloride (8 mg/kg body weight; Ceva
GmbH), and anesthesia was maintained if necessary.
The left femoral vein was cannulated with PE-50 tube
for Bengal Rose infusion. During the experiment, rectal
temperature was maintained at 37°C by a thermostati-
cally controlled heating pad (Föhr Medical Instruments).
Photothrombotic ischemia was induced in the rat frontal
cortex (right side) according to the method of Watson
[20]. Animals were placed in a stereotaxic frame, and
the scalp was incised for exposure of the skull surface.
For illumination, a laser spot of 8 mm diameter (G
Laser Technologies) was placed stereotaxically onto the
skull 0.5 mm anterior to the bregma and 4 mm lateral
from the midline. The skull was illuminated with a laser
for 15.5 minutes. During the first minute of illumina-
tion, the dye rose bengal (0,133 mL/kg body weight, 10
mg/mL saline) was injected intravenously. After surgery,
the catheter was removed and the animals were allowed
to recover from the anesthesia.
Donor cells
Bone marrow aspirates were obtained from two healthy
volunteers in the cell-processing laboratory (Institute for
Cardiovascular Regeneration, University of Frankfurt,
Germany). The Ethics Review Board of the Hospital of
the Johann Wolfgang Goethe University of Frankfurt,
Germany, approved the protocol, and the study was
conducted in accordance with the Declaration of Hel-
sinki. Written informed consent was obtained from each
volunteer. HBMC were isolated as described previously
[21]. Briefly, bone marrow aspirates were diluted with
0.9% NaCl (1:5), were filtrated (100 μm) and mononuc-
lear cells were isolated by density gradient centrifugation
using Ficoll (Cambrex; 800 × g, 20 min, without brake).
Mononuclear cells were washed for three times with 45
ml PBS (800 × g), were counted and sent by courier to
the laboratory (Department of Neurology, University of
Münster, Germany) where cell transplantations were
performed.
Intracarotid cell transplantation
Intracarotid injection of progenitor cells derived from
human bone marrow (hBMC) was carried out 3 days
after photothrombotic ischemia. Anesthesia was reinsti-
tuted and a midline neck incision was performed. The
right common carotid artery (CCA), the external carotid
artery (ECA) and the internal carotid artery (ICA) were
exposed under an operating microscope (Novex Hol-
land). The CCA and the ECA were ligated and a 5-0
suture was tied loosely at the origin of the ICA. A modi-
fied polyethylene catheter (PE-50, SIMS Portex Ltd) was
inserted through an arteriectomy in the CCA and gently
advanced into the ICA. Five million hBMC in 1 mL PBS
(n = 9) or PBS alone (n = 7) were injected at 1 mL/min
into each rat. Verum and control animals received daily
injections of cyclosporine A (10 mg/kg, i.p.) throughout
the experiment, commencing 24 hours before
transplantation.
Behavioral testing
Behavioral tests were performed before (baseline) and 2,
5, 14, 23 and 30 days after ischemia by an investigator
(K.K.) who was blinded to the experimental groups. For
Rotarod tests, rats were placed on an accelerating
Rotarod cylinder, and the time the animals remained on
the Rotarod was measured [22]. Speed was increased
f r o m4t o4 0r p mw i t h i n5m i n u t e s .T h et r i a le n d e di f
the animal fell off the rungs or gripped the device and
spun around for 2 consecutive revolutions without
attempting to walk on the rungs. An arbitrary time limit
of 600 seconds was set for rats on the Rotarod cylinder
in training and testing procedures. The animals were
trained 5 days before ischemia. The mean duration (sec-
onds) on the device was recorded with 3 measurements
1 day before surgery. Motor test data are presented as
percentage of mean duration (3 trials) on the Rotarod
compared with the internal control (2 days after
surgery).
For the adhesive-removal test, the somatosensory defi-
cit was measured both before and after ischemia [23,24].
All rats were familiarized with the testing environment.
In the initial test, 2 small pieces of adhesive-backed
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2) were used as bilat-
eral tactile stimuli occupying the distal-radial region at
the wrist of each forelimb. The rat was then returned to
ac a g e .T h et i m et or e m o v ee a c hs t i m u l u sf r o mf o r e -
limbs was documented by 3 trials per day for each fore-
paw. Individual trials were separated by a time shift of
at least 3 minutes. Before surgery, the animals were
trained for 5 days. Once the rats were able to remove
the dots within 10 seconds, they were subjected to
ischemia. An asymmetry score was calculated as ratio of
the difference of the impaired to the unimpaired fore-
limb to the sum of the impaired and the unimpaired
forelimb: (time to remove ipsilateral dot - time to
remove contralateral dot)/(time to remove ipsilateral dot
+ time to remove contralateral dot).
For the cylinder test, the rats were placed in a trans-
parent cylinder (16 cm diameter, 21 cm high) and video-
taped from below for 2 minutes [25]. Spontaneous wall
and ground touches of the impaired contralateral fore-
limb and the hindpaw were counted. The rats were
tested once before photothrombotic ischemia (baseline).
Data and statistical analysis
Values are presented as mean ± SEM. Statistical analyses
were carried out using the Statistical Package of Social
Sciences (version 15.0, SPSS Inc., Chicago, IL). Sensori-
motor measurements were analyzed with a 1-way
ANOVA for each time point, followed by the post hoc
Fisher protected least significance difference test. An a
error rate of 0.05 was taken as the criterion for
significance.
Results
There was no significant difference in the temperature
during surgery between cell-treated animals and con-
t r o l s .T h ep e r c e n tb o d yw e i g h td e c l i n ew a s4 %i nt h e
hBMC group and 8% in the placebo group (P > 0.05).
Since the photothrombotic stroke model causes in
somatosensory and motor deficits, we tested for both
qualities. Motor recovery was assessed by the Rotarod
test and the Cylinder test. Animals treated with hBMC
had no favorable recovery regarding motor function
(means ± SEM; P > 0.05, and means ± SEM; P > 0.05,
ANOVA) as shown by figure 1. Somatosensory deficits
also did not improve after hBMC treatment (means ±
SEM; P > 0.05, ANOVA) compared to placebo treated
rats (Figure 1).
Discussion
The treatment paradigm in the present study was cho-
sen on the basis of evidence from a clinical study that
showed efficacy of hBMC’s in patients with myocardial
infarction. We showed that hBMC shipment from a
cell-processing laboratory to a laboratory where cells are
transplanted is feasible. We analyzed the long-term
effects of an intraaterial hBMC treatment 3 days after
photothrombotic stroke in rats using a battery of beha-
vioral tests. Sensorimotor functions measured by the
Rotarod test, the adhesive-removal test and the cylinder
test were not improved after hBMC treatment compared
to placebo. So far limited data exist regarding the effi-
cacy of BMC’s in animal stroke models. It was shown,
that BMC’s improved functional recovery when intraate-
rially injected 90 minutes (10 million cells per rat), 6
hours (20 million cells per rat) and 24 hours (4 or 10
million cells per rat) after the onset of ischemia [26-28].
A decreased efficacy after a delayed treatment initiation
was reported after intravenous transplantation of BMC’s
[29,30]. This data suggest that hBMC treatment
improves the outcome when transplanted early after
stroke onset and that treatment three days after stroke
as performed in our study is beyond the window of
opportunity that allows functional recovery. The finding
is of particular interest since systematic evaluations of
the therapeutic time window after an intraarterial bone
marrow stem cell treatment in animal studies are lack-
ing so far. Nevertheless clinical trials were initiated that
investigate bone marrow stem cell treatment in stroke
patients at late time points between 9 and 90 days post-
stroke (http://www.clinical trials.gov; NCT00761982,
NCT00473057). The failed efficacy in our study empha-
sizes the importance of publishing negative preclinical
studies to prevent the publication bias due to unpub-
lished negative animal experimental studies which may
contribute to an inadequate design of clinical trials.
Moreover, the publication of negative results is neces-
sary to perform meta-analyses which were shown to be
an important tool to obtain a realistic impression of a
treatment’s efficacy in animal stroke studies [31,32].
Besides the late time point of transplantation another
potential reason for the failed improved functional
recovery after BMC treatment in our study might be the
human origin of the cells. However, in a vascular disease
model, the hindlimb ischemia model of the mouse,
transplantation of human BMC’s contributed to neovas-
cularisation and improved outcome [33]. In contrast to
our animal study BMC’s in clinical studies would be of
autologous origin and therefore no immunosuppression
would be required.
Conclusions
Our present study demonstrates that a treatment design
with hBMC’s that was shown to be successful in myo-
cardial infarction cannot simply adopted for stroke ther-
apy. A narrow window of opportunity to improve
functional recovery after ischemic stroke might be the
reason therefore.
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